# IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)

> **NCT04826159** · PHASE2 · COMPLETED · sponsor: **Imbria Pharmaceuticals, Inc.** · enrollment: 49 (actual)

## Conditions studied

- Type 2 Diabetes
- Diabetic Cardiomyopathies
- HFpEF - Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** IMB-1018972

## Key facts

- **NCT ID:** NCT04826159
- **Lead sponsor:** Imbria Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-21
- **Primary completion:** 2024-08-06
- **Final completion:** 2024-08-06
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04826159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04826159, "IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04826159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*